Alessandro Laganà

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Physical Activity

Chronic Myeloid Leukemia

Top Venues

Expert opinion on drug safety

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, Ida Carmosino, Claudia Ielo, Alessandro Costa, Lorenzo Torrieri, Matteo Totaro, Maurizio Martelli, Massimo Breccia
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety. Expert opinion on drug safety (2024)
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, Ida Carmosino, Claudia Ielo, Alessandro Costa, Lorenzo Torrieri, Matteo Totaro, Maurizio Martelli, Massimo Breccia
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety. Expert opinion on drug safety 23 (8) (2024)
Alessandro Laganà, Mauro Passucci, Sara Pepe, Emilia Scalzulli, Ida Carmosino, Alessandro Costa, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Massimo Breccia
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation. European journal of haematology (2024)
Alessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, Ida Carmosino, Claudia Ielo, Alessandro Costa, Lorenzo Torrieri, Matteo Totaro, Maurizio Martelli, Massimo Breccia
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety. Expert opinion on drug safety (2024)
Alessandro Laganà, Mauro Passucci, Sara Pepe, Emilia Scalzulli, Ida Carmosino, Alessandro Costa, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Massimo Breccia
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation. European journal of haematology 112 (6) (2024)
Alessandro Laganà, Sara Pepe, Emilia Scalzulli, Ida Carmosino, Mauro Passucci, Claudia Ielo, Alessandro Costa, Chiara Masucci, Daniela Diverio, Maurizio Martelli, Massimo Breccia
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission. European journal of haematology (2023)